| Literature DB >> 34177011 |
Mazhar Sher1,2, Aroosha Faheem3, Waseem Asghar1,2,4, Stefano Cinti5,6.
Abstract
There is a growing interest in the development of portable, cost-effective, and easy-to-use biosensors for the rapid detection of diseases caused by infectious viruses: COVID-19 pandemic has highlighted the central role of diagnostics in response to global outbreaks. Among all the existing technologies, screen-printed electrodes (SPEs) represent a valuable technology for the detection of various viral pathogens. During the last five years, various nanomaterials have been utilized to modify SPEs to achieve convincing effects on the analytical performances of portable SPE-based diagnostics. Herein we would like to provide the readers a comprehensive investigation about the recent combination of SPEs and various nanomaterials for detecting viral pathogens. Manufacturing methods and features advances are critically discussed in the context of early-stage detection of diseases caused by HIV-1, HBV, HCV, Zika, Dengue, and Sars-CoV-2. A detailed table is reported to easily guide readers toward the "right" choice depending on the virus of interest.Entities:
Keywords: Immunoassays; Nanomaterials; SARS CoV-2; Screen-printed electrodes (SPEs); Viruses
Year: 2021 PMID: 34177011 PMCID: PMC8215883 DOI: 10.1016/j.trac.2021.116374
Source DB: PubMed Journal: Trends Analyt Chem ISSN: 0165-9936 Impact factor: 14.908
Fig. 1Illustration of virus structures and their detection using the screen-printed electrodes. HIV-1 [38], Hepatitis C virus [39], Dengue virus [40], Zika Virus [41], Hepatitis B virus [42] and Sars-CoV-2 [43].
Fig. 2(a,b) The actual picture of developed disposable microchip containing screen-printed electrodes for CD4+ T cell quantification (Reprinted from Ref. [52]. Copyright 2019, Elsevier). (c) Illustration of the self-powered platform consisting of EGOFET and paper-based BFC for the quantification of HIV-1 p24 protein (Reprinted from Ref. [74]. Copyright 2020, Elsevier).
Fig. 3(a) Genetically engineered yeast cells based electrochemical immunoassay for detection of HCV (Reprinted from Ref. [86]. Copyright 2016, Elsevier). (b) The illustration of GBP yeast fusion proteins immobilization to the surface of a gold electrode (Reprinted from Ref. [88]. Copyright 2018, Elsevier).
Fig. 4(a) A step-by-step illustration of the pop-up PAD DNA sensor (Reprinted from Ref. [85]. Copyright 2020, Elsevier). (b) Screen-printed electrodes on PVC substrate immunosensor to detect HBV (Reprinted from Ref. [91]. Copyright 2021, Elsevier).
Fig. 5(a) Illustration of the nanoparticle enhanced method for the detection of ZIKV using a paper chip containing screen-printing electrodes consisting of graphene-silver nanocomposite ink (Reprinted from Ref. [37]. Copyright 2018, Royal Society of Chemistry). (b) The illustration of immunosensor based on ZnO nanostructures conjugated with ZIKV-NS1 antibody to detect ZIKV (Reprinted from Ref. [96]. Copyright 2019, Elsevier).
Fig. 6(a) An illustration of screen-printed carbon electrode-based immunosensor for the detection of dengue virus (Reprinted from Ref. [100]. Copyright 2018, Elsevier). (b) Graphene modified screen-printed electrodes based immunosensor to detect DENV IgG (Reprinted from Ref. [101]. Copyright 2021, Royal Society of Chemistry).
Fig. 7(a) Illustration of the magnetic beads-based assay for the rapid detection of SARS-CoV-2 (Reprinted from Ref. [102]. Copyright 2021, Elsevier). (b) AuNP based immunoassay on FTO electrode for detecting SARS-Cov-2 (Reprinted from Ref. [106]).
Summary of various methods of viral pathogens detection.
| Target | Platform | Sensing element | LOD | Time | Matrix | Ref. |
|---|---|---|---|---|---|---|
| HIV-1 viral particles | Printed flexible plastic microfluidic chip | Biotinylated polyclonal anti-HIV1 gp120 antibodies attached to streptavidin-coated magnetic microbeads. | 100 copies/mL | 60 min | Plasma | [ |
| CD4+ T cells | Point-of-care (POC) CD4 enumeration platform. | Biotinylated monoclonal anti-CD4 antibody-coated magnetic beads | 25 cells per μL | 5 min | Blood | [ |
| HIV-Antibodies | Microfluidic paper-based | HIV p24 protein | 300 pg/mL | 20 min | Serum | [ |
| HIV-1 p24 protein | Electrolyte-gated field-effect transistor (EGOFET) | anti-HIV1 p24 antibody | Approximately 1 fM range of proteins. | – | Blood | [ |
| HIV-DNA | Paper-based strip | Triplex forming oligonucleotides | 3 nM and 7 nM respectively for ssDNA and dsDNA. | – | Serum | [ |
| HIV p24 capsid protein | CNT-SPE | Monoclonal anti-HIV-1 p24 IgG1 | 2 pM | . | Serum | [ |
| anti-HCV core IgG | Au-SPE | HCV-core antigen | 32 nM | Approximately a few minutes time frame. | Serum | [ |
| HCV core antigen | Nafion@TiO2-SPE | Primary antibody | 25 fg/mL | – | Serum | [ |
| HCV antibodies | Smartphone-based | HCV core antigen linked to a gold binding peptide (GBP) | 12.3 pM | – | PBS | [ |
| Hepatitis B virus target DNA extracted from plasmid constructs. | Paper-based | Pyrrolidinyl PNA | 1.45 pM | – | Culture supernatants | [ |
| Hepatitis B Virus DNA | Paper-based | Magnetic microbeads, DNA probe, AgNPs | 85 pM | – | PBS buffer | [ |
| Hepatitis B surface antigen (HBsAg) | Immunosensor | Primary antibody | 0.17 μg/mL | – | Serum | [ |
| SARS-CoV-2 particles | CB-SPE immunosensor | Anti-S/N antibodies on magnetic beads | 19 ng/mL and 8 ng/mL in unprocessed saliva samples for S and N proteins, respectively | 30 min | Saliva | [ |
| nCovid-19 spike antigen (nCovid-19Ag) | Fluorine doped tin oxide electrode + AuNPs | nCovid-19 monoclonal antibody | 90 fM | 10–30 s | Saliva | [ |
| Zika Virus particles. | Paper-based microchip | Magnetic beads conjugated with anti-ZIKV monoclonal antibody | 100 viral particles per microliter. | Assay time is not specified. | Urine, plasma, semen | [ |
| Zika Virus NS1 antigen | ZnO nanostructures | Anti-ZIKV NS1 antibody. | 1 pg/mL | Assay time is not mentioned. | Urine | [ |
| ZIKV-specific antibodies | Screen-printed electrodes modified with carbon-nanotubes containing ZIKV-derived proteins. | ZIKV non-structural protein 1(NS1) and domain III of the envelope protein (EDIII) as biorecognition element. | Assay time is not specified. | Serum, saliva | [ | |
| Dengue virus NS1 | Impedimetric immunosensor consisting of BSA-SPCE modified with antibody. | anti-NS1 monoclonal antibody | 0.30 ng/mL | Assay time is not specified. | Serum | [ |
| Dengue Virus DNA Oligomer | Au-SPE | SiNWs/AuNPs | 1.63 pM | Assay time is not mentioned. | TE buffer | [ |
| Dengue virus antibodies | Graphene-SPE | Envelope glycoprotein domain III (EDIII) antigen. | 22.5 ng/mL | Assay time is not specified. | Serum | [ |